Analyst Ratings for Seattle Genetics (SGEN) [Sells]
SGEN Rating Summary
SGEN Price Target Summary
- Highest: $37.00 (Goldman Sachs)
- Lowest: $10.00 (Citadel Securities)
- Average: $20.14
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$20.14 (-43.7%)
Avg. $ Target:
$20.14 (-43.7%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/8/2012 | Cantor Fitzgerald | Downgrade | Sell (Hold) |
20.00 (30.00) |
24.47 | 35.75 | 46.1% | Details |
| 7/2/2012 | Piper Jaffray | Downgrade | Underweight (Neutral) |
20.00 (N/A) |
25.39 | 35.75 | 40.8% | Details |
| 12/9/2011 | WJB Capital | New Coverage | Sell (N/A) |
11.00 (N/A) |
17.98 | 35.75 | 98.83% | Details |
| 10/5/2011 | Summer Street | New Coverage | Sell (N/A) |
12.00 (N/A) |
20.34 | 35.75 | 75.76% | Details |
| 9/16/2011 | Madison Williams | New Coverage | Sell (N/A) |
10.00 (N/A) |
18.72 | 35.75 | 90.97% | Details |
| 8/8/2011 | Citadel Securities | New Coverage | Reduce (N/A) |
10.00 (N/A) |
13.84 | 35.75 | 158.31% | Details |
| 7/11/2011 | Chardan Capital | Downgrade | Sell (N/A) |
N/A (N/A) |
21.08 | 35.75 | 69.59% | Details |
| 3/9/2011 | BioLogic Equity Research | New Coverage | Sell (N/A) |
N/A (N/A) |
14.93 | 35.75 | 139.45% | Details |
| 11/1/2010 | Brean Capital | Downgrade | Sell (N/A) |
N/A (N/A) |
16.41 | 35.75 | 117.85% | Details |
| 8/4/2010 | WBB Securities | New Coverage | Sell (N/A) |
N/A (N/A) |
12.60 | 35.75 | 183.73% | Details |
